recently, we (23) and others (13) have identified that thrombin can also stimulate E-selectin expression leading to significant leukocyte rolling and adhesion.
Thrombin, a multifunctional serine protease, is generated through the activation of the coagulation cascade, but its effects also clearly contribute to inflammation. Indeed, studies (7, 31) are emerging to suggest that the inhibition of thrombin reduces the inflammatory response. One proposed mechanism is related to the ability of thrombin to recruit leukocytes. For example, neutrophil recruitment is blocked by antithrombin III (ATIII), an endogenous inhibitor of thrombin, following ischemia-reperfusion (24) . In addition, there is growing evidence that thrombin may contribute to atherosclerosis, rheumatoid arthritis, and other diseases wherein mononuclear leukocyte recruitment is a prominent feature (11, 21, 31) . Therefore, understanding the mechanisms by which thrombin induces leukocyte recruitment may be very important to defining novel anti-inflammatory therapeutics.
Our understanding of the intracellular signaling pathways that link thrombin and E-selectin-dependent leukocyte recruitment is incomplete. Essentially all studies that have examined E-selectin synthesis have used TNF-␣ as a stimulus. TNF-␣ stimulation has been shown to activate two separate pathways to induce E-selectin expression. One pathway involves activation of MKKK, leading to activation of MKK 4/7 and MKK 3/6 and subsequent activation of JNK and p38 MAPK, respectively (6, 10) . The activation of JNK and p38 MAPK leads to the activation of the transcription factor AP-1 (26) . TNF-␣ has also been shown to activate NF-B to induce transcription of E-selectin (5) . A recent report (14) from our laboratory has shown that like TNF-␣, thrombin also activates NF-B leading to E-selectin expression. However, blocking NF-B mobilization to the nucleus with proteasome inhibitor MG-132 only partially blocked E-selectin expression (60%) and leukocyte recruitment, suggesting an NF-B-independent pathway (14) . To our knowledge a role for p38 MAPK in thrombin-induced E-selectin expression and leukocyte recruitment has not been tested. The objective of our study was to systematically assess the functional importance of p38 MAPK as a mediator of E-selectin-dependent leukocyte recruitment. In addition, we compare the results to E-selectin-dependent leukocyte recruitment induced by TNF-␣ and rapid nonnuclear P-selectin-dependent leukocyte recruitment induced by thrombin.
Our data revealed an increase in both phosphorylation of p38 MAPK and p38 MAPK activity (phosphorylated ATF-2) in response to thrombin. Moreover, NF-B mobilization in response to thrombin can be blocked with p38 MAPK inhibitors, suggesting that p38 is upstream of NF-B in this particular intracellular pathway. Unexpectedly, there was complete inhibition of thrombin-induced leukocyte recruitment in response to two structurally different p38 MAPK inhibitors. This was specific for thrombin because neither p38 inhibitor had any effect on TNF-␣-induced leukocyte recruitment.
MATERIALS AND METHODS
Endothelium isolation. Human umbilical vein endothelial cells (HUVEC) were harvested and cultured from fresh human cords as previously described (23, 24) . Briefly, fresh cords were perfused with sterile PBS. The cords were then filled with collagenase (320 U/ml in PBS, Worthington Biochemical) and incubated for 20 min in warm PBS. After incubation, the cords were gently massaged to facilitate the release of endothelial cells from the vessel walls. The digest from the cords was drained into centrifuge tubes containing heat-inactivated FBS and centrifuged for 8-10 min at 1,100 revolutions/min. The cell pellet was resuspended in medium 199 (M199; GIBCO-BRL), supplemented with 20% FBS, antibiotic cocktail, and glutamine. The cell suspension was then seeded in fibronectin-coated T25 flasks. Once the cells were confluent (3-5 days), trypsin-EDTA (GIBCO-BRL) was used to rapidly detach the endothelial cells, which were then plated onto fibronectin-coated glass coverslips. All endothelium was from first-passage HUVEC.
P38 MAPK assay and immunoblots. Cell lysates were prepared using the p38 MAPK assay kit with slight modifications (New England Biolabs; Mississauga, Ontario, Canada). Briefly, monolayers were washed once with PBS and incubated on ice for 5 min with 1ϫ lysis buffer containing 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells were scraped off the dish, transferred to microcentrifuge tubes, sonicated for 5 s, and kept on ice. Samples were microcentrifuged at 14,000 revolutions/min for 10 min at 4°C and the supernatants (cell lysate) were transferred to new tubes. Fifty microliters of the cell lysate was used for Western blotting to detect phospho-p38 MAPK, and 200 l of the cell lysate was used in the immunoprecipitation to assess p38 MAPK activity.
Immunoprecipitation and kinase assay. Twenty microliters of immobilized phospho-p38 MAPK (Thr180/Tyr182) monoclonal antibody was added to 200 l of cell lysate and incubated with gentle rocking overnight at 4°C. Samples were microcentrifuged at 14,000 revolutions/min for 30 s at 4°C. The pellet was washed twice with 1ϫ lysis buffer and 1ϫ kinase buffer and kept on ice. For the kinase assay, the pellet was suspended in 50 l of 1ϫ kinase buffer supplemented with 200 M ATP and 2 g ATF-2 fusion protein and incubated 30 min at 37°C. The reaction was terminated with 25 l 2ϫ SDS sample buffer [100 l 20% SDS, 50 l dithiothreitol (DTT), and 500 l 2ϫ sample buffer]. Samples were boiled for 5 min and resolved on 10% SDS-PAGE gel. Gels were transferred onto polyvinylidene difluoride membrane using a semidry apparatus. Membranes were blocked in 2% skim milk/Tween 20 Tris-based sodium (TTBS), washed once with TTBS, and incubated with phospho-ATF-2 or phosphop38 antibody (1:1,000) in TTBS with gentle agitation overnight at 4°C. Membranes were washed with TTBS and incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:2,000) and horseradish peroxidaseconjugated anti-biotin antibody (1:1,000) to detect biotinylated protein markers in 2% skim milk/TTBS at room temperature. After a secondary antibody was given, the membranes were washed with TTBS and proteins were detected using 1ϫ LumiGLO (0.5 ml 20ϫ LumiGLO, 0.5 ml 20ϫ peroxide, and 9.0 ml water) with gentle agitation for 1 min at room temperature and exposed to X-ray film.
ELISA for cell surface adhesion molecule expression. Briefly, confluent HUVEC were seeded onto fibronectincoated 48-well ELISA plates, treated with various stimuli, fixed with 1% formalin, and blocked with 1% BSA. The endothelial cells were labeled with 5 g/ml of ES1 (E-selectin antibody). They were then washed and labeled with a peroxidase-labeled goat anti-mouse IgG (1 g/ml, DAKO). After a final wash, a substrate system (TMB-One Step, DAKO) was added for color development and the color reaction was stopped with 0.18 M H 2SO4. The plates were read at 450 nm.
Electrophoretic mobility shift assay. After treatment with HUVEC, the cells were lysed and nuclear extracts were prepared as described elsewhere with modifications (19, 25) . Briefly, monolayers were incubated on ice for 15 min in buffer (10 mM HEPES, 0.1 mM EDTA, 10 mM KCl, 1 M DTT, 0.33 M PMSF, 5 mg/ml of leupeptin, and 2.1 mg/ml of aprotinin, 0.6% Nonidet P-40). The monolayers were harvested by scraping and the crude nuclei obtained from lysis were collected by centrifugation (45 s at 14,000 revolutions/min) and resuspended in buffer C (20 mM HEPES, 5 mM EDTA, 0.42 M NaCl, 0.33 M PMSF, 1 M DTT, and 10% glycerol). The nuclei were incubated on a rocking platform at 4°C for 30 min and microcentrifuged for 10 min at 4°C. The resulting supernatants were stored at Ϫ70°C until needed. Protein concentrations were determined with Bio-Rad protein assay (Bradford Assay).
Oligonucleotides (5Ј-AGGGACTTTCCGCTGGGGACTTTC-C-3Ј, 5Ј-GGAAAGTCCCCAGCGGAAAGTCCCT-3Ј) for NF-B were synthesized on a synthesizer (Oligo model 1000; Beckman), end labeled with ␥-[ 32 P]ATP (3,000 Ci/mmol) (Amersham) and T4 DNA kinase (New England Biolabs), and annealed by heating the oligonucleotides to 75°C for 10 min and were then slowly cooled to room temperature. Unincorporated label was removed by gel filtration (Microspin G-25 columns; Pharmacia). Binding reaction mixtures contained 5 l binding buffer [50 mM Tris ⅐ HCl, 500 m M NaCl, 5 mM EDTA, 1 M MgCl2 (5 mM), 20% glycerol, 1 M DTT (5 mM)], 2-5 g nuclear extract protein, 3.3 g/l poly(dI-dC) (2.95 mg/ml), and the final volume was brought to 27 l with ddH2O. The reaction mixture was kept at room temperature for 15 min, followed by the addition of 100-200 fmol of [ 32 P]DNA and incubated at room temperature for 20 min. Electrophoresis was performed on a 6% nondenaturing polyacrylamide gel at 15 mA for 1 h in 0.5ϫ Tris-borate EDTA. Gels were dried and DNA protein complexes were analyzed by autoradiography. Competition studies were performed by the addition of unlabeled double-stranded oligonucleotides (20-fold in excess of labeled probe) to the binding reaction mixtures.
Flow chamber assay. To study leukocyte-endothelial cell interactions under shear conditions in vitro, a whole blood flow chamber assay was used as described (27) . Glass coverslips plated with confluent endothelial cells were mounted onto a polycarbonate chamber with parallel plate geometry. The flow chamber was placed onto the stage of an inverted microscope (Zeiss; Don Mills, Ontario, Canada), enclosed in a warm-air cabinet maintained at 37°C. Endothelial monolayers were visualized at ϫ200 magnification using phase-contrast microscopy. A syringe pump (Harvard Apparatus; S. Natick, MA) was used to draw whole blood over the endothelial monolayer. Whole blood was taken from healthy individuals and 30 U/ml of heparin (1,000 U/ml) was added to prevent coagulation. Heparin was shown not to affect leukocyte-endothelium interactions, whereas other anticoagulants, such as citrate, abolished interactions (27) . The perfusion rate was set at 10 dyn/cm 2 . Experiments were recorded via a charge-coupled device camera (Hitachi Denshi; San Jose, CA) and a videocassette recorder (Panasonic; Secaucus, NJ) attached to the microscope. Rolling and adherent cell counts were made through video analysis.
Experimental protocol. Leukocyte recruitment was examined on endothelial monolayers exposed to thrombin for 10 min (P-selectin dependent), 4-h postthrombin treatment or, for comparison, monolayers treated with TNF-␣ (25 ng/ml) for 4 h. The concentration of TNF used is a standard dose based on optimal concentrations from our laboratory and what others have used. To determine the effects of thrombin (0.5 U/ml, from human plasma, Sigma-Aldrich; Ontario, Canada) on endothelium at the 4-h time point, the medium was removed, and the coverslips were washed once with warm sterile PBS. The endothelium was stimulated with thrombin for 3 min. Thrombin was removed and the media were placed back onto the coverslips. Four hours later, the coverslips were placed in the flow chamber and perfused briefly with Hanks' buffered salt solution (HBSS; composed of Ca 2ϩ , Mg 2ϩ , and sodium bicarbonate). We (23) previously reported that this concentration of thrombin induced optimal E-selectin expression, whereas higher concentrations induced less E-selectin expression due to significant injury to the endothelium. In addition, 3 min were optimal for E-selectin expression because prolonged exposure to thrombin (4 h) injured the endothelium (detachment from substratum).
To determine the effect of thrombin on endothelium at 10 min, confluent monolayers of endothelium were perfused with HBSS buffer containing thrombin (0.5 U/ml) for 10 min and used immediately in experiments. Whole blood was perfused at 10 dyn/cm 2 over thrombin-stimulated endothelium for 5 min, followed by perfusion with HBSS to clear nonattached red blood cells and leukocytes. Five fields of view were recorded for 20 s each, and rolling and adhesion were determined using playback analysis as previously described (27) . If a leukocyte remained stationary for at least 10 s, it was defined as adherent. In control experiments, the endothelium was perfused with HBSS without thrombin for 10 min and whole blood was perfused as described above.
For the p38 MAPK studies, the HUVEC were pretreated with the p38 MAPK inhibitors SKF86002 (10 M) and SB203580 (10 M) (Calbiochem; San Diego, CA), for 1 h before thrombin or TNF-␣ treatment. Preliminary experiments involving ATF-2 phosphorylation had indicated the need for the p38 MAPK inhibitors to be present throughout the kinase assay to significantly inhibit the p38 activity. Therefore, the inhibitors were readded during the kinase reaction for 10 min at 37°C before the addition of ATP and ATF-2 fusion protein. In some experiments, 2 mg/ml Refludan, a recombinant hirudin analog and a specific thrombin inhibitor, was incubated with thrombin (0.1 U/ml) for 15 min before stimulation of endothelium.
Statistics. All data are reported as means Ϯ SE. Student's t-test was used to compare between groups with a Bonferroni correction for multiple comparisons. Significance was set at P Ͻ 0.05. All experiments within a series (including controls) were done on the same day with the use of endothelial cells from the same cord to minimize variability.
RESULTS

Thrombin induces phosphorylation of p38 MAPK.
Preliminary experiments were performed to determine the time course for thrombin-induced phosphorylation of p38 MAPK. HUVEC were exposed to thrombin (0.5 U/ml) for 3 min and after 5 min, 20 min, or 1 h, cell lysates were prepared and stained with the use of a phospho-p38 MAPK antibody. At 20 min, the phosphorylated p38 MAPK was optimal compared with the other two time points (data not shown). The 20-min time point was subsequently used for all the MAPK studies. Figure 1 shows thrombin-induced phosphorylation of p38 MAPK. HUVEC were pretreated with the p38 MAPK inhibitors SB-203580 and SKF86002 for 1 h before thrombin treatment. These inhibitors function by competitive binding to the ATP pocket of p38 MAPK (10) . HUVEC were treated with thrombin for 3 min washed, and medium was placed back into the dish for 20 min, after which cell lysates were prepared. As Fig.   Fig. 1 . Thrombin-induced phosphorylation of p38 MAPK. Human umbilical vein endothelial cells (HUVEC) were pretreated with 10 M SB-203580 (SB) or 10 M SKF86002 (SKF) and then stimulated with 0.5 U/ml of thrombin (Thr) or 25 ng/ml of tumor necrosis factor-␣ (TNF-␣). Cell lysates were prepared and immunoblotted with anti-phospho-p38 MAPK (A) and then stripped and reprobed with anti-p38 MAPK antibodies (B) to determine equal loading. The blot is representative of three separate experiments. Densitometry was carried out on the immunoblots to quantitate the relative changes in p38 MAPK phosphorylation (C). There was sevenfold increase in phosphorylated p38 MAPK compared with untreated (Unt) HUVEC and, as evident, both of the inhibitors had no effect on the activation of p38 MAPK. The data in C are represented as the average of three separate experiments.
1A demonstrates, there was an increase in phosphorylated p38 MAPK in response to thrombin stimulation (lane 2) compared with untreated HUVEC (lane 1). As expected, the inhibitors did not affect phosphorylation of p38 MAPK (lanes 3 and 4) . A large increase in phosphorylated p38 MAPK was observed with TNF-␣ (lane 5). Neither SB-203580 nor SKF86002 affected TNF-␣-induced phosphorylation of p38 MAPK (lanes 6 and 7) consistent with previous literature (15) . The gels were stripped and reprobed with an antibody against p38 MAPK to determine that equivalent amounts of protein were placed in each lane (Fig. 1B) . Densitometry was carried out to quantitate the relative amounts of phosphorylated p38 MAPK. As Fig. 1C demonstrates, there was an approximately sevenfold increase in phosphorylated p38 MAPK in thrombintreated compared with untreated endothelium. The increase in phosphorylated p38 MAPK was not affected by the inhibitors. A similar pattern was observed in TNF-␣-treated HUVEC, and this was also unaffected by the inhibitors.
SB-203580 and SKF86002 decreased p38 MAPK activity. The activity of p38 MAPK was then examined with the use of the downstream effector of p38 MAPK activation, phospho-ATF2. Figure 2A demonstrates an increase in phospho-ATF2 (lane 2) versus unstimulated HUVEC (lane 1). SB-203580 and SKF86002 reduced the activity of p38 MAPK (lanes 3 and 4) . TNF-␣ also increased activity of p38 MAPK (lane 5) versus unstimulated HUVEC (lane 1). SB-203580 and SKF86002 reduced TNF-␣ induced p38 MAPK activity (lanes 6 and 7) . The membranes were stripped and reprobed with an antibody against ATF-2 to confirm equal loading (Fig. 2B) . Figure 2C shows densitometry of ATF-2 phosphorylation and reveals a significant increase in response to thrombin stimulation, which is blocked by SB-203580 and SKF86002. The twofold increase in phosphorylated ATF-2 was decreased to control levels for thrombin as well as for TNF-␣.
We then wanted to examine whether thrombin activated JNK and ERK MAPK. Figure 3A shows that thrombin induced increased phosphorylation of JNK MAPK (lane 2) compared with untreated HUVEC (lane 1). The inhibitors did not affect phosphorylation of JNK MAPK (lanes 3 and 4) . A large increase in phosphorylated JNK MAPK was observed in HUVEC treated with TNF-␣ (lane 5). Neither SB-203580 nor SKF86002 affected TNF-␣-induced phosphorylation of JNK MAPK (lanes 6 and 7) . The gels were stripped and reprobed with an antibody against JNK MAPK to determine that equivalent amounts of protein were placed in each lane (Fig. 3B) . Figure 3C shows that the ERK MAPK pathway was not significantly induced in response to thrombin stimulation and that neither SB-203580 nor SKF86002 affected this MAPK.
The pyridinyl imidazole inhibitor SB-203580 has been suggested to block the phosphorylation and activation of protein kinase B (PKB) by inhibiting phosphoinositide-dependent protein kinase-1 (18) . In another series of experiments, we tested whether the concentration (10 M) of SB-203580 had any nonspecific effects on phosphorylation of PKB (AKT) kinase pathway. HUVEC were pretreated with the SB-203580 for 1 h before thrombin stimulation and then lysed, and immunoblots for phosphorylated-AKT were performed. HUVEC stimulated for 5 min, 20 min, and 1 h with thrombin showed a slight increase in phosphorylated-AKT compared with untreated cells (data not shown). Pretreating with the SB-203580 compound did not block this increase in phosphorylated-AKT (data not shown). 4) . B: gels were stripped and reprobed with an antibody against JNK MAPK to determine that equivalent amounts of protein were placed in each lane. C and D: ERK MAPK pathway was not induced in response to thrombin stimulation and neither SB nor SKF affected this MAPK. 
Thrombin-induced mobilization of NF-B is blocked with p38 MAPK inhibitor SKF86002.
We previously reported that thrombin induced NF-B mobilization. We next asked whether p38 MAPK contributed to this process. Figure 4 illustrates NF-B mobilization in response to thrombin stimulation. HUVEC were pretreated for 1 h with the p38 MAPK inhibitor SKF86002 before thrombin treatment. As previously reported by us and others, thrombin specifically induced NF-B DNA binding complexes in HUVEC (lane 3) compared with the untreated HUVEC (lane 1). Competitive labeling verified the specificity of the binding (lanes 2, 4,  and 6 ). Most importantly, Fig. 4 , lane 5, shows that SKF86002 reduced NF-B activation to levels below those observed in controls. Quantitation of the EMSA showed a significant increase in NF-B DNA binding, and this was reduced by 83% in the presence of the inhibitor (data not shown).
P38 MAPK inhibition reduced E-selectin expression on thrombin-treated endothelium. Table 1 shows the data for cell surface E-selectin expression on endothelium treated for 4 h with two concentrations of thrombin. There was a significant increase in E-selectin expression with both concentrations of thrombin compared with untreated endothelium. Pretreating the endothelium with SB-203580 for 1 h eliminated Eselectin expression at the lower concentrations of thrombin and partly inhibited E-selectin expression by 55% at the higher concentrations. The value of 0.188 U of fluorescence under basal conditions reflects background fluorescence because no leukocyte recruitment is seen under basal conditions. Figure 5 shows leukocyte rolling and adhesion on untreated endothelium and endothelium treated with thrombin. When whole blood was perfused over untreated endothelium, 5 Ϯ 2 rolling leukocytes per field of view were noted, whereas endothelium treated with thrombin for 3 min and whole blood perfused 4 h later supported an average of 50-60 rolling leukocytes per field of view (Fig. 5A) . Pretreating with SKF86002 for 1 h reduced rolling leukocytes to untreated levels (5 Ϯ 3 rolling leukocytes per field of view). The number of adherent cells followed a similar pattern. The number of adherent leukocytes after thrombin stimulation increased more than fivefold. SKF86002 reduced the number of adherent leukocytes to control levels (Fig. 5B) . At the end of the experiments, the coverslips were stained (GeimsaWright stains), revealing that 70% of the leukocytes were neutrophils. The other 30% were mononuclear cells. An insufficient number of cells were seen on SKF86002-treated endothelium for analysis of leukocyte cell type.
P38 inhibitors blocked leukocyte recruitment on 4 h postthrombin-stimulated HUVEC.
On the basis of previous work (14) showing that an NF-B inhibitor reduced leukocyte recruitment by 60%, we did not expect to see 100% inhibition with SKF86002. To ensure that this was not specific to SKF86002, we repeated the experiments with SB-203580. Figure 6 demonstrates a similar pattern of leukocyte recruitment with this second p38 MAPK inhibitor.
We examined TNF-␣-treated HUVEC to determine whether the p38 MAPK inhibitor SKF86002 would inhibit leukocyte recruitment. Figure 7 shows a significant increase in rolling and adherent leukocytes with TNF-␣ compared with unstimulated HUVEC. The av- (lanes 2, 4, and 6) . The data are representative of three separate experiments. Values are means Ϯ SE; n, no. of vessels. ND, not determined. E-selectin expression was determined using a standard ELISA with ES1 (E-selectin Ab, 5 g/ml) as the primary antibody. * P Ͻ 0.05, relative to untreated (Ϫ) endothelium; † P Ͻ 0.05, relative to thrombin treatment (ϩ) alone.
erage number of rolling leukocytes on TNF-␣-treated HUVEC were observed to be 80 Ϯ 16 cells per field of view, whereas under untreated conditions there were on average two cells per field of view (Fig. 7A) . Adherent leukocytes with TNF-␣ stimulation were observed to increase Ͼ20-fold (Fig. 7B) . The majority of leukocytes were neutrophils. In contrast to the thrombin results, SKF86002 did not block TNF-␣-induced leukocyte recruitment (Fig. 7) .
P38 inhibitors did not block leukocyte recruitment on 10-min thrombin-stimulated HUVEC. To determine whether p38 MAPK mediated all adhesive responses induced by thrombin, we examined leukocyte recruitment at 10 min. It has been well established that 10-min thrombin stimulation induces a P-selectin-dependent (protein-synthesis independent) pathway of leukocyte recruitment. Figure 8 demonstrates the rolling (Fig. 8A) and adherent (Fig. 8B ) leukocytes on untreated endothelium and endothelium treated with thrombin for 10 min. Few leukocytes were observed to be rolling or adherent on untreated endothelium, whereas 10 min of thrombin treatment supported an average of 28 Ϯ 10 rolling and 101 Ϯ 39 adherent leukocytes per field of view (Fig. 8, A and B) . Pretreatment of the endothelium with SKF86002 did not affect leukocyte recruitment at this time point. SB-203580 showed a similar pattern of recruitment (data not shown). Although the thrombin was kept on the endothelium for the entire time of this acute experiment, rolling began as early as 3-5 min postthrombin administration, and the p38 MAPK inhibitors neither delayed nor reduced leukocyte rolling and adhesion.
To ensure that the thrombin-induced recruitment was indeed a result of the enzymatic activity of thrombin, some monolayers were treated with Refludan. Figure 9 demonstrates that thrombin-induced rolling and adhesion is completely blocked in the presence of Refludan. Therefore, this confirms that the activation of the endothelium in these assays is dependent on thrombin enzymatic activity. Fig. 5 . p38 inhibitor SKF blocks leukocyte rolling and adhesion on endothelium stimulated with thrombin. There was a significant decrease in rolling (A) and adherent (B) leukocytes on endothelium pretreated with SKF. For 4-h thrombin stimulation, coverslips were stimulated with thrombin for 3 min and whole blood was perfused 4 h later. All of the experiments were done with the same concentration of thrombin (0.5 U/ml). Five fields of view were recorded and analyzed for rolling and adherent leukocytes. Values represent average leukocyte rolling and adhesion observed per field of view. * P Ͻ 0.05, relative to untreated endothelium; † P Ͻ 0.05, relative to thrombin treatment alone (n ϭ 3). Fig. 6 . SB blocks leukocyte rolling and adhesion on endothelium stimulated with thrombin. There was a significant decrease in rolling (A) and adherent (B) leukocytes on endothelium pretreated with SB. * P Ͻ 0.05 relative to untreated endothelium; † P Ͻ 0.05 relative to thrombin treatment alone (n ϭ 3).
DISCUSSION
In this study, we demonstrate that thrombin causes the phosphorylation and activation of p38 MAPK, which leads to NF-B-dependent and -independent synthesis of E-selectin. Our data also show that this pathway is functional inasmuch as all thrombin-induced leukocyte recruitment at 4 h was inhibited by two well-characterized p38 MAPK inhibitors. By direct contrast, the very rapid (within 5-10 min) leukocyte recruitment associated with thrombin, involving the mobilization of presynthesized P-selectin from WeibelPalade bodies is not dependent on p38 MAPK. Clearly, thrombin can activate at least two distinct pathways to induce surface expression of two distinct adhesion molecules, ultimately resulting in the recruitment of neutrophils at 5-10 min and neutrophils and mononuclear cells at 4 h. Finally, our data reveal that inhibition of p38 MAPK alone is insufficient to inhibit TNF-␣-induced leukocyte recruitment, suggesting activation of p38-independent pathways for leukocyte recruitment. Therefore, whereas both thrombin and TNF-␣ induced phosphorylation of p38 MAPK, this event was absolutely necessary for thrombin but not TNF-␣-induced leukocyte recruitment.
Activation of p38 MAPK appears to be important in regulating cell responses to stress. Heat, oxidative stress, cytokines, and even thrombin have been shown to activate this MAPK member in various cell types (16, 17, 20, 28) . Recently, the focus on p38 MAPK has revealed an important role for this MAPK in numerous important endothelial responses. Endothelial morphological changes to shear stress, endothelial adhesion Fig. 7 . SKF did not block leukocyte rolling and adhesion on endothelium stimulated with TNF-␣. There was no decrease in rolling (A) or adherent (B) leukocytes observed on endothelium pretreated with SKF. * P Ͻ 0.05 relative to untreated; n ϭ 3. Fig. 8 . Rolling (A) and adherent (B) leukocytes on endothelium stimulated with thrombin (0.5 U/ml) for 10 min. For 10-min stimulation, thrombin was added to HBSS and perfused over the endothelium for 10 min, followed by whole blood perfusion for 5 min. All the experiments were done with the same concentration of thrombin (0.5 U/ml). Five fields of view were recorded and analyzed for rolling and adherent leukocytes. Values represent average leukocyte rolling and adhesion observed per field of view. * P Ͻ 0.05 relative to untreated endothelium (n ϭ 4). molecule expression in response to TNF-␣, endothelial motility, and growth in response to VEGF or IGF-␥, and even endothelial chemokine production have all been shown to involve p38 MAPK (1, 20, 26, 29) . Our study adds to the growing list of stimuli and growing list of functions played by endothelial p38 MAPK. These data also suggest that different pathways must be used to induce morphological changes versus inflammatory changes versus motility and even growth. Clearly, on activation of p38 MAPK with shear stress or VEGF, downstream phosphorylation of two kinases, MAPK-activated protein kinase-2 and -3, leads to phosphorylation of a small heat shock protein-27 that enhances F-actin polymerization and cytoskeletal changes (9) . In this study, we show that activation of endothelium with thrombin also leads to activation of p38 MAPK; however, this results in phosphorylation of ATF-2 and c-Jun (26) , which then presumably act as transcriptional activators, leading to adhesion molecule synthesis. The mechanisms that regulate which p38-dependent pathway is invoked are likely related to phosphorylation of different sites on p38 or phosphorylation of different p38 subunits (␣, ␤, ␥, and ␦), which dictate differential downstream events.
We previously demonstrated that NF-B inhibition significantly reduces thrombin-induced leukocyte recruitment. In that study, we proposed that the residual recruitment was NF-B-independent and perhaps p38 MAPK dependent. To our surprise, the p38 inhibitors SB-203580 and SKF86002 blocked all of the thrombininduced leukocyte recruitment, suggesting that p38 MAPK mediated both NF-B-dependent and independent cellular recruitment. Although, in some systems p38 MAPK appears to be distinct from NF-B, p38 MAPK has been reported to be involved in some NF-B-dependent biology (8, 12, 22, 30) . For example, the specific involvement of p38 MAPK in lipopolysaccharide-induced NF-B activation and inducible nitric oxide synthase expression in macrophages has been demonstrated. In the presence of SB-203580, NF-B DNA binding and inducible nitric oxide synthase mRNA production were dramatically reduced (12) . Clearly, in these and our own study, p38 MAPK is an important activator of NF-B. Our own data suggest that the activation of p38 MAPK to induce NF-B translocation to the nucleus to induce E-selectin expression is the major pathway for leukocyte recruitment by thrombin. Although the p38 MAPK inhibitors eliminated E-selectin-dependent rolling, they reduced E-selectin expression by only 55%. Clearly, inhibition in this E-selectin expression is sufficient to completely inhibit E-selectin function, in the flow chamber assays.
The pyridinyl imidazole compound SB-203580 has been shown to be active in a variety of animal models of acute and chronic inflammation (10), making p38 MAPK inhibition a potential anti-inflammatory strategy. Despite its pharmacological efficacy for p38 MAPK inhibition, it has been suggested that in certain cell types this compound nonspecifically activates and/or inhibits signaling molecules other than p38 MAPK. Birkenkamp et al. (4) have demonstrated that 10 M concentrations of SB-203580 activated the ERK MAPK pathway in an erythroleukemic cell line, which subsequently enhanced NF-B transcriptional activity. Lali et al. (18) showed that the same concentration of inhibitor blocked phosphorylation and activation of PKB kinase through inhibition of PKB kinase phosphoinositide-dependent protein kinase-1 in an interleukin-2-stimulated T cell line CT6. There are numerous studies that have not seen these nonspecific effects of p38 MAPK inhibitors (1, 20) . In our system, using primary HUVEC we did not observe the activation of ERK MAPK in the presence of SB-203580 nor did we observe any effect on PKB phosphorylation.
These data may have direct implications with respect to therapeutic approaches to disease. Whereas TNF-␣ is a ubiquitous cytokine that is increased in many disease states to induce immune cell recruitment, the inflammatory spectrum of thrombin is somewhat more restricted to vascular diseases, including Fig. 9 . Rolling (A) and adherent (B) leukocytes on endothelium stimulated with thrombin (0.1 U/ml) for 10 min in the presence or absence of Refludan. Refludan (2 mg/ml) was incubated with thrombin for 15 min at room temperature before thrombin was added to HBSS and perfused over the endothelium for 10 min, followed by whole blood perfusion for 5 min. Five fields of view were recorded and analyzed for rolling and adherent leukocytes. Values represent average leukocyte rolling and adhesion observed per field of view. * P Ͻ 0.05 relative to thrombin treatment alone (n ϭ 3).
ischemia-reperfusion, atherosclerosis, and vasculitis. Because inhibition of p38 MAPK has such dramatically different effects with respect to efficacy for thrombin and TNF-␣, investigation of the new classes of p38 inhibitors in thrombin-induced inflammatory processes is warranted.
